Dave Kappos Speaks at IPWatchdog’s 2022 Webinar on Patent Holdout and SEP Licensing
April 28, 2022
On April 27, 2022, Cravath partner David J. Kappos participated in a webinar hosted by IPWatchdog. The panel, entitled “Patent Holdout and the Quest for Balance in SEP Licensing,” discussed the effects of patent holdout on standard essential patent licensing, how arbitration can encourage swifter resolution of disputes, and the impact of recent case law on the interaction between innovators and implementers.
Related Practices & Industries
Speakers
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
Related News & Insights
Deals & Cases
April 26, 2022
Artel’s Acquisition by Advanced Instruments
On April 26, 2022, Artel, a global leader in low volume liquid delivery measurement and quality assurance used throughout the life science industry, and Advanced Instruments, a leading manufacturer of analytical instruments and services for the clinical, biopharmaceutical and food & beverage sectors, announced the execution of a definitive agreement for Advanced Instruments to acquire Artel. Cravath is representing Artel in connection with the transaction.
Deals & Cases
February 28, 2022
Viatris’s $3.335 Billion Combination of its Biosimilars Portfolio with Biocon Biologics
On February 28, 2022, Viatris Inc. (“Viatris”) announced that it reached a definitive agreement with Biocon Biologics Limited (“Biocon Biologics”) to contribute its biosimilars portfolio to Biocon Biologics, which will become a uniquely positioned, vertically integrated company expected to be a global biosimilars leader. Under the terms of the agreement, Viatris will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities, amounting to 2022 estimated revenue of approximately $875 million and 2022 estimated adjusted EBITDA of approximately $200 million, in exchange for pre-tax consideration of up to $3.335 billion, which represents a transaction multiple of 16.5x of estimated 2022 biosimilars adjusted EBITDA. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
February 22, 2022
Taro’s Acquisition of Alchemee
On February 22, 2022, Taro Pharmaceutical Industries Ltd. (“Taro”), a multinational, science-based pharmaceutical company, and Galderma, the world’s largest independent dermatology company, announced they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company, from Galderma. The agreement between Galderma and Taro includes Alchemee’s business and assets around the world, including the Proactiv brand. Cravath is representing Taro in connection with the transaction.
Deals & Cases
December 27, 2021
FactSet’s $1.9 Billion Acquisition of S&P Global’s CUSIP Global Services
On December 27, 2021, FactSet, a global provider of integrated financial information and analytical applications, announced that it has entered into a definitive agreement to acquire CUSIP Global Services, an operator of market standard security identifiers, from S&P Global for $1.925 billion in cash. Cravath is representing FactSet in connection with the transaction.
